Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,339 result(s) found. Displaying page 1,684 of 2,217.
    «« First « Previous 1680  1681  1682  1683  1684  1685  1686  1687  1688  Next» Last»»
    EudraCT Number: 2014-001473-14 Sponsor Protocol Number: MK-3475-042 Start Date*: 2014-10-14
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metast...
    Medical condition: Non-Small Cell Lung Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) LT (Completed) LV (Completed) PT (Completed) PL (Completed) EE (Completed) BG (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-001930-93 Sponsor Protocol Number: GC-627-04 Start Date*: 2017-01-13
    Sponsor Name:Generon (Shanghai) Corporation Ltd.
    Full Title: A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
    Medical condition: Women, between 18 and 75 years of age that have been diagnosed with Stage II-IV breast cancer in the adjuvant or metastatic setting and are scheduled to undergo chemotherapy. This is a profilaxis ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    19.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-001812-80 Sponsor Protocol Number: 11-12-23/03-intern-6470 Start Date*: 2011-11-25
    Sponsor Name:Maastro Clinic
    Full Title: Non invasive imaging of [18F]HX4 with Positron-Emission-Tomography (PET) in Head and Neck Cancer.
    Medical condition: Patients with histological or cytological confirmed squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx, larynx, T2-T3-T4, any N, M0
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000309-64 Sponsor Protocol Number: AL-ACC-01 Start Date*: 2019-10-24
    Sponsor Name:Ayala Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label, Multi-Center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
    Medical condition: Adenoid cystic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053231 Adenoid cystic carcinoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003553-15 Sponsor Protocol Number: GC-627-05 Start Date*: 2018-06-22
    Sponsor Name:Generon (Shanghai) Corporation Ltd.
    Full Title: A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
    Medical condition: Women, between 18 and 75 years of age that have been diagnosed with Stage I-III breast cancer and are scheduled to undergo chemotherapy. This is a prophylaxis for myleotoxic chemotherapy induced ne...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10005329 - Blood and lymphatic system disorders 10016288 Febrile neutropenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-004844-20 Sponsor Protocol Number: ADXS001-02 Start Date*: 2017-05-08
    Sponsor Name:Advaxis, Inc
    Full Title: Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence)
    Medical condition: High-risk locally advanced carcinoma of the cervix (HRLACC) following concurrent chemotherapy and radiation therapy.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10008231 Cervical cancer recurrent LLT
    19.1 100000004864 10008229 Cervical cancer LLT
    19.1 100000004864 10008236 Cervical cancer stage IV LLT
    19.1 100000004864 10008235 Cervical cancer stage III LLT
    19.1 100000004864 10008234 Cervical cancer stage II LLT
    19.1 100000004864 10008233 Cervical cancer stage I LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002052-24 Sponsor Protocol Number: MERCY Start Date*: 2017-12-14
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Continuous infusion versus intermittent administration of meropenem in critically ill patients. A multicenter randomized double blind trial.
    Medical condition: We are planning a large multicentre randomized controlled study to confirm the beneficial effect of continuous infusion of meropenem against bolus administration as indicated by a composite outcome...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10062357 SIRS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003768-29 Sponsor Protocol Number: DAY101-102 Start Date*: 2022-04-05
    Sponsor Name:DOT Therapeutics-1 Inc. (Day One)
    Full Title: A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
    Medical condition: Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001369-25 Sponsor Protocol Number: HPT30/J/17 Start Date*: 2018-03-19
    Sponsor Name:INFAI Institut für biomedizinische Analytik und NMR Imaging GmbH
    Full Title: The Sensitivity and Specificity of the Modified Helicobacter Test INFAI Using New Test Meal with 13C-Urea Breath Test in Helicobacter Pylori Positive and Negative Patients with Dyspepsia and GERD T...
    Medical condition: Diagnosis of Helicobacter pylori infection for patients taking proton pump inhibitors (PPI) with one day break of medication instead of two weeks prior to the test
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000623-40 Sponsor Protocol Number: BCD-100-5/FERMATA Start Date*: 2019-12-02
    Sponsor Name:JSC BIOCAD
    Full Title: An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bev...
    Medical condition: Advanced Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008236 Cervical cancer stage IV LLT
    21.1 100000004864 10008231 Cervical cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Prematurely Ended) AT (Prematurely Ended) DK (Completed) FI (Prematurely Ended) PL (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003398-91 Sponsor Protocol Number: ABI-007-PANC-003 Start Date*: 2014-05-15
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma
    Medical condition: Subjects With Surgically Resected Pancreatic Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10033602 Pancreatic adenocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) HU (Completed) ES (Ongoing) IT (Completed) PT (Completed) BE (Completed) FI (Completed) IE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001696-16 Sponsor Protocol Number: SOLUCOM Start Date*: 2021-10-28
    Sponsor Name:Vestre Viken Health Trust
    Full Title: Sotorasib in advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities
    Medical condition: Advanced KRASG12C-mutated non-small cell lung cancer patients with comorbidities
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025044 Lung cancer LLT
    25.1 100000004850 10069759 KRAS mutation LLT
    22.0 100000004850 10075674 KRAS codon 12 and 13 mutation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001104-36 Sponsor Protocol Number: IIV-291 Start Date*: 2016-06-01
    Sponsor Name:RIVM
    Full Title: Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands
    Medical condition: immunological response to an extra mumps immunization (in healthy volunteers)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2023-001028-40 Sponsor Protocol Number: RIV-PN-201 Start Date*: 2024-01-15
    Sponsor Name:United Therapeutics Corp
    Full Title: Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study
    Medical condition: Persistant Pulmonary Hypertension of the Newborn (PPHN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-003155-38 Sponsor Protocol Number: CNTO1959LUN2001 Start Date*: 2020-08-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects with Active Lupus Nephritis
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-005151-83 Sponsor Protocol Number: MUCUS Start Date*: 2018-10-26
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE
    Medical condition: Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003607-35 Sponsor Protocol Number: C0221002 Start Date*: 2020-10-26
    Sponsor Name:Pfizer Inc.
    Full Title: PHASE 2, 24-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH FO...
    Medical condition: Focal Segmental Glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) PL (Completed) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005306-49 Sponsor Protocol Number: MK-0683-092 Start Date*: 2008-09-03
    Sponsor Name:Department of Haematology, Herlev Hospital, University of Copenhagen
    Full Title: A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia
    Medical condition: patients with polycythaemia vera or essential thrombocythaemia or myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036057 Polycythaemia vera LLT
    9.1 10015493 Essential thrombocythaemia LLT
    12.1 10028537 Myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-006042-13 Sponsor Protocol Number: MEDI-TOLP-01 Start Date*: 2022-03-28
    Sponsor Name:MEDITOP Gyógyszeripari Kft.
    Full Title: A randomized double blind placebo controlled multicenter study to assess the efficacy and tolerability of tolperisone as add on treatment with standardized NSAID of acute non specific low back pain.
    Medical condition: Acute, non-specific low back pain
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10024891 Low back pain LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-003773-17 Sponsor Protocol Number: dex_version1 Start Date*: 2017-06-12
    Sponsor Name:Karolinska University Hospital
    Full Title: A prospective randomized open label study Intranasal dexmedetomidine versus inhaled nitrous oxide for children age 3 – 15 years for procedural sedation and analgesia in pediatric emergency departme...
    Medical condition: sedation for emergency procedures
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1680  1681  1682  1683  1684  1685  1686  1687  1688  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 08:54:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA